Anesthesia and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Center for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha Medical College and Hospitals, Saveetha University, Chennai, India.
BMC Complement Med Ther. 2024 Sep 17;24(1):335. doi: 10.1186/s12906-024-04639-3.
Multiple trauma has serious complications, which increases the risk of morbidity and mortality in the patients. This study aimed to evaluate the impact of supplementation with phytosomal curcumin on clinical and laboratory factors in critically ill patients with multiple trauma.
In this double-blind trial, 53 patients with multiple trauma, who were admitted to the intensive care unit (ICU) were randomized to receive either 2 capsules, each capsule containing 250 mg phytosomal (a total of 500 mg daily) as an intervention group or 2 identical capsules (placebo capsules), each containing 250 mg maltodextrin for 7 days. Clinical and laboratory were parameters assessed before and after the intervention.
After seven days of intervention, the mean increase from baseline in the Glasgow coma scale (GCS) score was significantly higher in the curcumin compared with the placebo group (P-value: 0.028), while the reduction in the APACHE-II score in the curcumin group was greater than that the placebo group in a marginally non-significant fashion (P-value: 0.055). Serum total bilirubin (P-value: 0.036) and quantitative C-reactive protein (CRP) (P-value: 0.044) levels significantly decreased while potassium (P-value: 0.01) significantly increased in the curcumin compared with the placebo group. Moreover, supplementation with phytosomal curcumin significantly increased platelet count (P-value: 0.024) as compared with placebo. The 28-day mortality rate was 7.7% (n: 2 patients) and 3.7% (n: 1 patients) in the placebo and curcumin groups, respectively (P-value > 0.05).
Phytosomal curcumin had beneficial effects on several clinical and laboratory factors including GCS, APACHEII, serum total bilirubin, CRP, and platelet count in ICU-admitted patients with multiple trauma.
IRCT20090306001747N1, Available on: https://www.irct.ir/trial/52692 . The first registration date was 12/01/2021.
多发创伤有严重的并发症，这增加了患者发病和死亡的风险。本研究旨在评估补充植物素姜黄素对多发创伤危重症患者的临床和实验室因素的影响。
在这项双盲试验中，53 名多发创伤患者被随机分配到接受 2 粒胶囊（每粒胶囊含有 250 毫克植物素姜黄素，每日共 500 毫克）作为干预组或 2 粒相同的胶囊（安慰剂胶囊），每粒胶囊含有 250 毫克麦芽糊精，为期 7 天。在干预前后评估了临床和实验室参数。
干预 7 天后，姜黄素组的格拉斯哥昏迷评分（GCS）从基线的平均升高明显高于安慰剂组（P 值：0.028），而姜黄素组的急性生理与慢性健康状况评分 II（APACHE-II）评分下降幅度大于安慰剂组，但差异无统计学意义（P 值：0.055）。与安慰剂组相比，姜黄素组血清总胆红素（P 值：0.036）和定量 C 反应蛋白（CRP）（P 值：0.044）水平显著降低，而钾（P 值：0.01）水平显著升高。此外，与安慰剂相比，姜黄素组的血小板计数显著增加（P 值：0.024）。安慰剂组和姜黄素组的 28 天死亡率分别为 7.7%（n：2 例）和 3.7%（n：1 例）（P 值>0.05）。
植物素姜黄素对 ICU 收治的多发创伤患者的几个临床和实验室因素，包括 GCS、APACHEII、血清总胆红素、CRP 和血小板计数，有有益的影响。
IRCT20090306001747N1，可在以下网址查询：https://www.irct.ir/trial/52692。首次注册日期为 2021 年 1 月 12 日。
